Carcinoma, Ductal
6
0
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer
Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Multipeptide Vaccine for Advanced Breast Cancer
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer